Gwo Xi Stem Cell Company has established the R&D center for cell therapy product development at Hsinchu Biomedical Science Park since 2011.

We are committed to developing stem cell medicines that have the potential to help patients with unmet medical needs.

Our production platform fully comply with medical regulations (Good Tissue Practice, GTP) in Taiwan. There are four stem cell new drugs being put into clinical trial produced by this platform. Among them, GXNPC1 (Chronic Stroke) and GXCPC1 (Osteoarthritis) are moving forward to Phase III trial, which they use autologous ADSCs and allogeneic ADSCs, respectively.

We are establishing PIC/S GMP grade stem cell preparation factory (15,225 m2 built-out space) to put stem cell-based medicinal products into practice and progressively enlarge our production line in a scale-up level.